HIV Pipeline: Chart on Drugs in Development

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

More on HIV Medications

The Center for AIDS

HIV Pipeline: Chart on Drugs in Development

Source: Ben Cheng, Project Inform⁴

Summer 2002

Compound	Class of Compound	Phase of Development	Pharmaceutical Company
ACH-126,443 (L-Fd4C)	nucleoside analog RT inhibitor	Phase 1	Achilleon
ADA	zinc finger	Phase 1-2	Hubriphar
AMD-3465³	CXCR4 antagonist	Preclinical	AnorMed
AMD-8445³	entry inhibitor	Preclinical	AnorMed
Atazanavir (BMS-232623)	protease inhibitor	Phase 2-3¹	Bristol-Myers Squibb
BCH-10618 (DOTC)	nucleoside analog RT inhibitor	Preclinical	Shire Biochem
BEA-005³	nucleoside analog RT inhibitor	Preclinical	Medivir
Beta-D-Fd4C³	nucleoside analog RT inhibitor	Preclinical	Vion
Beta-L-Fd4C³	nucleoside analog RT inhibitor	Preclinical	Vion
BMS-806	entry inhibitor	Phase 1	Bristol-Myers Squibb
Calanolide A	non-nucleoside RT inhibitor	Phase 2	Sarawak Medichem
Capravirine	non-nucleoside RT inhibitor	Phase 2	Pfizer/Agouron
DAPD	nucleoside analog RT inhibitor	Phase 1-2	Triangle Pharmaceuticals
DEHSPM	inhibits hypusin/eIF-5A	Phase 1	SunPharm
DPC 083	non-nucleoside RT inhibitor	Phase 1-2	DuPont Pharmaceuticals²
DPC 681	protease inhibitor	Preclinical	Dupont Pharmaceuticals²
DPC 684	protease inhibitor	Preclinical	Dupont Pharmaceuticals²
DPC 961	non-nucleoside RT inhibitor	Phase 1	DuPont Pharmaceuticals²
Emivirine (MKC-442)	non-nucleoside RT inhibitor	Phase 3	Triangle Pharmaceuticals
Emtricitabine (FTC)	nucleoside analog RT inhibitor	Phase 3	Triangle Pharmaceuticals
HI-236³	non-nucleoside RT inhibitor	Preclinical	Wayne Hughes Institute
Hu5A8³	binding inhibitor	Preclinical	Tanox
Hydroxyurea	inhibits cellular factors	Phase 2-3	Bristol-Myers Squibb
L-870,810	integrase inhibitor	Phase 1	Merck & Co.
LB-71350³	protease inhibitor	Preclinical	LG Chemical
Mycophenlate	inhibits cellular factors	Phase 1-2	Hoffman-La Roche
Peldesine	inhibits cellular factors	Phase 1	Biocryst
Pentfuside (T-20)	fusion inhibitor	Phase 3¹	Trimeris/Roche
Phosphazid³	nucleoside analog RT inhibitor	Preclinical	Viscount
PNU142721	non-nucleoside RT inhibitor	Preclinical	Pharmacia
PRO 140	CCR5 antagonist	Preclinical	Progenics
PRO 367	entry inhibitor	Phase 1	Progenics
PRO 542	attachment inhibitor	Phase 1-2	Progenics
RD4-2217³	non-nucleoside RT inhibitor	Preclinical	Tosoh
Resveratrol	inhibits cellular factors	Phase 1	Pharmascience
S-1360	integrase inhibitor	Phase 1-2	Shionogi Pharmaceuticals
SCH C	CCR5 antagonist	Phase 1	Schering Plough
SCH D	CCR5 antagonist	Preclinical	Schering Plough
SJ-3366³	non-nucleoside RT inhibitor	Preclinical	Samjin
T-1249	fusion inhibitor	Phase 1	Trimeris/Roche
TAK 449	CCR5 antagonist	Preclinical	Takeda
Tipranavir	protease inhibitor	Phase 1-2	Boehringer Ingelheim
TMC 125	non-nucleoside RT inhibitor	Phase 2	Tibotec Virco
TMC 120	non-nucleoside RT inhibitor	Phase 2	Tibotec Virco
TMC 126	protease inhibitor	Phase 1	Tibotec Virco
UC-781³	non-nucleoside RT inhibitor	Preclinical	Uniroyal
UK-427,857	CCR5 antagonist	Preclinical	Pfizer
VX-175/GW433908 (amprenavir prodrug)	protease inhibitor	Phase 2-3	Vertex/GlaxoSmithKline

Note: RT stands for Reverse Transcriptase

Available in expanded access
Dupont Pharmaceuticals sold its anti-HIV drug Sustiva and its HIV research pipeline to Bristol-Myers Squibb in 2001
No information available
Ben Cheng is now the Project Manager at the Forum for Collaborative HIV Research in Washington, DC (www.hivforum.org).

Back to the RITA! Summer 2002 contents page.